Immune responses elicited by apoB-100-derived peptides in mice

Immunologic Research

Volumn 56, Issue 1, 2013, Pages 96-108

  Pierides, Chrysoulla ^a   Bermudez Fajardo, Alexandra ^a   Fredrikson, Gunilla Nordin ^b   Nilsson, Jan ^b   Oviedo Orta, Ernesto ^a,c  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Dendritic cells; Immune response; Lymphocyte; Peptides; Regulatory T cells

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN B100 P2; APOLIPOPROTEIN B100 P210; APOLIPOPROTEIN B100 P45; DENDRITIC CELL VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MALE; MICROENVIRONMENT; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TISSUE DISTRIBUTION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD4; ANTIGENS, CD8; APOLIPOPROTEIN B-100; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELLS, CULTURED; DENDRITIC CELLS; HUMANS; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-10; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TH1-TH2 BALANCE; VACCINES, SUBUNIT;

EID: 84876417974     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-013-8383-1     Document Type: Article

References (32)

1. Kaperonis EA, Liapis CD, Kakisis JD, Dimitroulis D, Papavassiliou VG. Inflammation and atherosclerosis. Eur J Vasc Endovasc Surg. 2006;31:386-93.
2. Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke. 2006;37:1923-32.
3. Nilsson J, Hansson GK. Autoimmunity in atherosclerosis: a protective response losing control? J Intern Med. 2008;263:464-78.
4. Yen HC, Lee FY, Chau LY. Analysis of the T cell receptor V beta repertoire in human aortic aneurysms. Atherosclerosis. 1997;135:29-36.
5. Chyu KY, Nilsson J, Shah PK. Active and passive immunization for atherosclerosis. Curr Opin Mol Ther. 2007;9:176-82.
6. Davidson MH, Maki K, Umporowicz D, Wheeler A, Rittershaus C, Ryan U. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis. 2003;169:113-20.
7. Gaofu Q, Jie W, Xin Y, Roque RS, Jingjing L. Expressing and purifying an anti-atherosclerosis polypeptide vaccine in Escherichia coli. Protein Expr Purif. 2004;36:198-206.
8. Komori T. CETi-1. AVANT. Curr Opin Investig Drugs. 2004;5:334-8.
9. Fredrikson GN, Andersson L, Soderberg I, Dimayuga P, Chyu KY, Shah PK, Nilsson J. Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression. Autoimmunity. 2005;38:171-9.
10. van Wanrooij EJ, de Vos P, Bixel MG, Vestweber D, van Berkel TJ, Kuiper J. Vaccination against CD99 inhibits atherogenesis in low-density lipoprotein receptor-deficient mice. Cardiovasc Res. 2008;78(3):590-6.
11. Bauminger S, Wilchek M. The use of carbodiimides in the preparation of immunizing conjugates. Methods Enzymol. 1980;70:151-9.
12. Cochet O, Teillaud J-L, Sautes C. Immunological techniques made easy. Chichester: Wiley; 1998.
13. Reichlin M. Use of glutaraldehyde as a coupling agent for proteins and peptides. Methods Enzymol. 1980;70:159-65.
14. Fredrikson GN, Bjorkbacka H, Soderberg I, Ljungcrantz I, Nilsson J. Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo B-100 transgenic mice without inducing an increase in peptide-specific antibodies. J Intern Med. 2008;264:563-70.
15. Kool M, Soullie T, van Nimwegen M, Willart MA, Muskens F, Jung S, Hoogsteden HC, Hammad H, Lambrecht BN. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med. 2008;205:869-82.
16. Fredrikson GN, Soderberg I, Lindholm M, Dimayuga P, Chyu KY, Shah PK, Nilsson J. Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences. Arterioscler Thromb Vasc Biol. 2003;23:879-84.
17. Alvarez D, Vollmann EH, von Andrian UH. Mechanisms and consequences of dendritic cell migration. Immunity. 2008;29:325-42.
18. Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nat Immunol. 2000;1:199-205.
19. Pulendran B, Banchereau J, Maraskovsky E, Maliszewski C. Modulating the immune response with dendritic cells and their growth factors. Trends Immunol. 2001;22:41-7.
20. Grohmann U, Fallarino F, Bianchi R, Belladonna ML, Vacca C, Orabona C, Uyttenhove C, Fioretti MC, Puccetti P. IL-6 inhibits the tolerogenic function of CD8 alpha+ dendritic cells expressing indoleamine 2,3-dioxygenase. J Immunol. 2001;167:708-14.
21. Novak N, Bieber T. 2. Dendritic cells as regulators of immunity and tolerance. J Allergy Clin Immunol. 2008;121:S370-4. quiz S413.
22. Blanco P, Palucka AK, Pascual V, Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev. 2008;19:41-52.
23. Vremec D, Pooley J, Hochrein H, Wu L, Shortman K. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J Immunol. 2000;164:2978-86.
24. Combadière C, Potteaux S, Rodero M, Simon T, Pezard A, Esposito B, Merval R, Proudfoot A, Tedgui A, Mallat Z. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation. 2008;117(13):1649-57.
25. Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, Stray-Pedersen A, Ocheltree EL, Greenberg PD, Ochs HD, Rudensky AY. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci USA. 2006;103:6659-64.
26. Nishioka T, Shimizu J, Iida R, Yamazaki S, Sakaguchi S. CD4+CD25+Foxp3+ T cells and CD4+CD25-Foxp3+ T cells in aged mice. J Immunol. 2006;176:6586-93.
27. Stoop JN, Claassen MA, Woltman AM, Binda RS, Kuipers EJ, Janssen HL, van der Molen RG, Boonstra A. Intrahepatic regulatory T cells are phenotypically distinct from their peripheral counterparts in chronic HBV patients. Clin Immunol. 2008;129:419-27.
28. Vu MD, Xiao X, Gao W, Degauque N, Chen M, Kroemer A, Killeen N, Ishii N, Chang Li X. OX40 costimulation turns off Foxp3+ Tregs. Blood. 2007;110:2501-10.
29. Wohlfert EA, Nichols FC, Nevius E, Clark RB. Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms. J Immunol. 2007;178:4129-35.
30. Smith TR, Kumar V. Revival of CD8+ Treg-mediated suppression. Trends Immunol. 2008;29:337-42.
31. Goncalves I, Nitulescu M, Ares MP, Fredrikson GN, Jansson B, Li ZC, Nilsson J. Identification of the target for therapeutic recombinant anti-apoB-100 peptide antibodies in human atherosclerotic lesions. Atherosclerosis. 2009;205:96-100.
32. Klingenberg R, Lebens M, Hermansson A, Fredrikson GN, Strodthoff D, Rudling M, Ketelhuth DF, Gerdes N, Holmgren J, Nilsson J, Hansson GK. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30:946-52.